deltatrials
Completed PHASE2 NCT00004888

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer

A Safety and Efficacy Study of Doxil and Taxotere ± Herceptin in Advanced Breast Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Recurrent Breast Cancer Stage IV Breast Cancer
Interventions docetaxel laboratory biomarker analysis pegylated liposomal doxorubicin hydrochloride trastuzumab
Updated 6 times since 2017 Last updated: May 7, 2014 Started: Jan 31, 2001 Primary completion: Apr 30, 2008 Completion: May 31, 2009

A PHASE2 clinical study on Recurrent Breast Cancer and Stage IV Breast Cancer, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 6 data snapshots since 2001. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Jan 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States